Peeling-Off Labels. Mounting Evidence for Benefit of Drug-Eluting Stents With Off-Label Use**Editorials published in the Journal of American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 50, Issue 21, 2007, Pages 2037-2038

  Büttner, Heinz Joachim ^a   Neumann, Franz Josef ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PACLITAXEL; RAPAMYCIN;

ANGIOCARDIOGRAPHY; DRUG APPROVAL; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; EDITORIAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OFF LABEL DRUG USE; PRIORITY JOURNAL; RESTENOSIS; STATISTICAL SIGNIFICANCE; STENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS AS TOPIC; CONSUMER PRODUCT SAFETY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIAL INFARCTION; PACLITAXEL; SIROLIMUS; TREATMENT OUTCOME;

EID: 36048978624     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.08.020     Document Type: Editorial

References (13)

1. Farb A., and Boam A.B. Stent thrombosis redux-the FDA perspective. N Engl J Med 356 (2007) 984-987
2. Camenzind E., Steg P.G., and Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115 (2007) 1440-1455
3. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
4. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
5. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
6. Kastrati A., and Schoemig A. Drug-eluting stents is their future as bright as their past?. J Am Coll Cardiol 50 (2007) 146-148
7. Abbott J.D., Voss M.R., Nakamura M., et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 50 (2007) 2029-2036
8. Win H.K., Caldera A.E., Maresh K., et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
9. Beohar N., Davidson C.J., Kip K.E., et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (2007) 1992-2000
10. Marzocchi A., Saia F., Piovaccari G., et al. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation 115 (2007) 3181-3188
11. Jensen L.O., Maeng M., Kaltoft A., et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 50 (2007) 463-470
12. Serruys P.W., Ong A.T.L., Morice M.C., et al. Arterial Revascularisation Therapies Study part II-sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroInterv 1 (2005) 147-156
13. Serruys P.W., Ong A.T., van Herwerden L.A., et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 46 (2005) 575-581